Drug for treatment of type II diabetes

A technology for type 2 diabetes and drugs, applied in drug combinations, metabolic diseases, pharmaceutical formulations, etc., can solve the problems of unsatisfactory clinical efficacy of western medicine, carcinogenicity, and difficult for patients to adhere to.

Active Publication Date: 2015-11-04
SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] The incidence of diabetes in my country is showing a continuous upward trend. With the advancement of science and technology, various hypoglycemic western medicines have been used clinically one after another. However, the emergence of various side effects and limitations of application make the clinical efficacy of these western medicines unsatisfactory.
Although insulin has saved the lives of countless diabetic patients, it needs multiple subcutaneous injections a day, and many patients find it difficult to persist.
Recently published glucagon-like peptide-1 (GLP-1) receptor agonists (such as exenatide, liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as citrate Gliptin) is controversial due to its potential carcinogenic or acute pancreatitis risk

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for treatment of type II diabetes
  • Drug for treatment of type II diabetes
  • Drug for treatment of type II diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Preparation process of Jinbuhuan extract and detection of extract components, drug efficacy experiment

[0036] 1. Extraction process:

[0037] Jinbuhuan 4.8kg was extracted and refluxed three times with 95% methanol aqueous solution, each time for 4 hours, filtered, combined extracts, and concentrated under reduced pressure to obtain 1227.68g of dark brown total extract.

[0038] Suspend the extract in water, extract with petroleum ether, dichloromethane, ethyl acetate, and n-butanol in sequence, and evaporate the four extracts to dryness to obtain extract, in which 74.21 g of petroleum ether extract, dichloromethane layer Extract 298.81g, ethyl acetate layer extract 236.15g, n-butanol layer extract 401.79g, water layer extract 193.29g.

[0039] Take 50 g of the ethyl acetate layer extract and pass it through a normal-phase silica gel column, and use a gradient of dichloromethane-methanol (wherein the volume ratio of dichloromethane and methanol is 30:1, 9:1...

Embodiment 2

[0042] Example 2 In vitro anti-diabetic experiment of Jinbuhuan total extract

[0043] (1) HL1C rat liver cancer cells (hereinafter referred to as HL1C cells) are a kind of rat liver tumor H4IIE cell line, which contains a stably transfected Pck1 promoter gene, which can promote the expression of chloramphenicol acetyltransferase, and is suitable for use in Research on the Pck1 gene, the target of antidiabetic drugs. HL1C cells were cultured in high glucose DMEM containing 10% fetal bovine serum (4.5g / L glucose). Place it at 37°C with 5% CO 2 , Incubate in an incubator with saturated humidity, change the medium every 24 hours, and cultivate for 3 to 5 days for experimental use.

[0044] (2) After HL1C cells were co-incubated with different concentrations of total extracts, total RNA was extracted with Trizol, and then cDNA was extracted with a reverse transcription kit, and the level of Pck1 mRNA was detected by SYBR Green fluorescent probe method. The detection conditions w...

Embodiment 3

[0051] Example 3 Anti-type II diabetes experiment of gentiopicroside and / or swertiroside in vitro

[0052] (1) HL1C rat liver cancer cells were cultured in vitro in DMEM containing 10% fetal bovine serum. Place it at 37 °C with 5% CO 2 , incubating in an incubator with saturated humidity, changing the medium every 24 hours, and culturing for 3 to 5 days for experimental use.

[0053] (2) After HL1C cells were co-incubated with 30 μg / mL gentiopicroside for 6 hours, the total RNA was extracted by Trizol, and then the cDNA was extracted with a reverse transcription kit, and the Pck1 mRNA level was detected by the SYBR Green fluorescent probe method. °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.

[0054] (3) HL1C cells were mixed with gentiopicroside, swertipicroside, and different concentrations of gentiopicroside and swertipicroside (the mass ratios of the two were 2:1, 5:1, 10:1, 1 :10, 1:5 and 1:2) mixtures were incubated for 15 min, then diges...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a drug for treatment of type II diabetes, and the drug comprises medicinal ingredients of gentiopicroside and / or sweroside, or comprises the medicinal ingredients of a panax notoginseng total extract including the two components. Experiments show that the panax notoginseng total extract, gentiopicroside and sweroside two monomers and a mixture of the gentiopicroside and the sweroside have the role of good resistance to the type II diabetes, and can inhibit phosphorylation of type II diabetes target spot PEPCK and Akt, Erk and the like. The effect of the mixed gentiopicroside and sweroside is better than the effect of other monomer and single use of the gentiopicroside and sweroside two monomers. A new research channel for treatment of type II diabetes is opened, and medicinal value of the panax notoginseng is further developed.

Description

technical field [0001] The invention relates to a medicine for treating type two diabetes. Background technique [0002] The incidence of diabetes in our country shows a continuous upward trend. With the advancement of science and technology, various hypoglycemic western medicines have been used clinically one after another. However, the emergence of various side effects and limitations of application make the clinical efficacy of these western medicines unsatisfactory. Although insulin has saved the lives of countless diabetic patients, it requires multiple subcutaneous injections a day, and many patients find it difficult to persist. Recently published glucagon-like peptide-1 (GLP-1) receptor agonists (such as exenatide, liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as citrate Gliptin) is controversial due to its potential carcinogenic or acute pancreatitis risk. Therefore, people urgently need to seek more and better new hypoglycemic drugs. [0003] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K36/59A61P3/10
Inventor 黄先菊李竣梅枝意
Owner SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap